Influence of apolipoprotein E, age and aortic site on calcium phosphate induced abdominal aortic aneurysm in mice

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 204-212

  Wang, Yutang ^a   Krishna, Smriti M ^a   Moxon, Joseph ^a   Dinh, Tam Nguyen ^a   Jose, Roby J ^a   Yu, Hongyou ^a   Golledge, Jonathan ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Abdominal aortic aneurysm; Age; Apolipoprotein E; Calcium phosphate; Cholesterol; Mice

Indexed keywords

APOLIPOPROTEIN E; CALCIUM PHOSPHATE; GAMMA INTERFERON; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; CHOLESTEROL; CYTOKINE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTA ANEURYSM; ADVENTITIA; AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA ARCH; AORTIC CALCIFICATION; APOPTOSIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CALCIFICATION; CELL EXPANSION; CELL INFILTRATION; CELLULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEGRADATION; DISEASE PREDISPOSITION; ELASTIC LAMELLAR DEGRADATION; INFRA RENAL AORTA; MACROPHAGE INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THORACIC AORTA; ANIMAL; BLOOD; BLOOD PRESSURE; C57BL MOUSE; CHEMISTRY; GENETICS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY;

ANIMALS; AORTA; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; APOPTOSIS; BLOOD PRESSURE; CALCIUM PHOSPHATES; CHOLESTEROL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CYTOKINES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84901854151     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.033     Document Type: Article

References (52)

1. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
2. Rughani G., Robertson L., Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev 2012, 9. CD009536.
3. Assar A.N. Medical treatment of small abdominal aortic aneurysm. JCardiovasc Surg (Torino) 2012, 53:517-525.
4. Golledge J., Norman P.E. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 2011, 217:57-63.
5. Moxon J.V., Padula M.P., Herbert B.R., Golledge J. Challenges, current status and future perspectives of proteomics in improving understanding, diagnosis and treatment of vascular disease. Eur J Vasc Endovasc Surg 2009, 38:346-355.
6. Paraskevas K.I., Mikhailidis D.P., Perrea D. Experimental models of abdominal aortic aneurysms: an overview. Curr Pharm Des 2008, 14:325-337.
7. Chaer R.A., DeRubertis B.G., Hynecek R., Kent K.C., Faries P.L. Models of abdominal aortic aneurysm: characterization and clinical applications. Vascular 2006, 14:343-352.
8. Daugherty A., Cassis L.A. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004, 24:429-434.
9. Yamanouchi D., Morgan S., Stair C., Seedial S., Lengfeld J., Kent K.C., et al. Accelerated aneurysmal dilation associated with apoptosis and inflammation in a newly developed calcium phosphate rodent abdominal aortic aneurysm model. JVasc Surg 2012, 56:455-461.
10. Johnsen S.H., Forsdahl S.H., Solberg S., Singh K., Jacobsen B.K. Carotid atherosclerosis and relation to growth of infrarenal aortic diameter and follow-up diameter: the Tromso Study. Eur J Vasc Endovasc Surg 2013, 45:135-140.
11. Norman P.E., Muller J., Golledge J. The cardiovascular and prognostic significance of the infrarenal aortic diameter. JVasc Surg 2011, 54:1817-1820.
12. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
13. Matsuura F., Wang N., Chen W., Jiang X.C., Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. JClin Invest 2006, 116:1435-1442.
14. Harris J.D., Evans V., Owen J.S. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther 2006, 8:275-287.
15. Gerdes L.U., Lindholt J.S., Vammen S., Henneberg E.W., Fasting H. Apolipoprotein E genotype is associated with differential expansion rates of small abdominal aortic aneurysms. Br J Surg 2000, 87:760-765.
16. Ashton H.A., Buxton M.J., Day N.E., Kim L.G., Marteau T.M., Scott R.A., et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002, 360:1531-1539.
17. Scott R.A., Vardulaki K.A., Walker N.M., Day N.E., Duffy S.W., Ashton H.A. The long-term benefits of a single scan for abdominal aortic aneurysm (AAA) at age 65. Eur J Vasc Endovasc Surg 2001, 21:535-540.
18. Alcorn H.G., Wolfson S.K., Sutton-Tyrrell K., Kuller L.H., O'Leary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1996, 16:963-970.
19. Nordon I., Brar R., Taylor J., Hinchliffe R., Loftus I.M., Thompson M.M. Evidence from cross-sectional imaging indicates abdominal but not thoracic aortic aneurysms are local manifestations of a systemic dilating diathesis. JVasc Surg 2009, 50:171-176.e1.
20. Ward A.S. Aortic aneurysmal disease. A generalized dilating diathesis. Arch Surg 1992, 127:990-991.
21. Seto S.W., Krishna S.M., Yu H., Liu D., Khosla S., Golledge J. Impaired acetylcholine-induced endothelium-dependent aortic relaxation by caveolin-1 in angiotensin II-infused apolipoprotein-E (ApoE-/-) knockout mice. PLoS One 2013, 8:e58481.
22. Chiou A.C., Chiu B., Pearce W.H. Murine aortic aneurysm produced by periarterial application of calcium chloride. JSurg Res 2001, 99:371-376.
23. Rush C., Nyara M., Moxon J.V., Trollope A., Cullen B., Golledge J. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics 2009, 10:298.
24. Lupachyk S., Watcho P., Hasanova N., Julius U., Obrosova I.G. Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress. Free Radic Biol Med 2012, 52:1255-1263.
25. Flondell-Site D., Lindblad B., Kolbel T., Gottsater A. Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms. Cytokines 2009, 46:211-215.
26. Golledge A.L., Walker P., Norman P.E., Golledge J. Asystematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers 2009, 26:181-188.
27. Middleton R.K., Bown M.J., Lloyd G.M., Jones J.L., London N.J., Sayers R.D. Characterisation of interleukin-8 and monocyte chemoattractant protein-1 expression within the abdominal aortic aneurysm and their association with mural inflammation. Eur J Vasc Endovasc Surg 2009, 37:46-55.
28. Takagi H., Manabe H., Kawai N., Goto S.N., Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg 2009, 9:437-440.
29. Helske S., Syvaranta S., Kupari M., Lappalainen J., Laine M., Lommi J., et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J 2006, 27:1495-1504.
30. Krishna S.M., Seto S.W., Moxon J.V., Rush C., Walker P.J., Norman P.E., et al. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol 2012, 181:706-718.
31. Trollope A., Moxon J.V., Moran C.S., Golledge J. Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol 2011, 20:114-123.
32. Wang Y., Krishna S., Golledge J. The calcium chloride-induced rodent model of abdominal aortic aneurysm. Atherosclerosis 2013, 226:29-39.
33. Gertz S.D., Kurgan A., Eisenberg D. Aneurysm of the rabbit common carotid artery induced by periarterial application of calcium chloride invivo. JClin Invest 1988, 81:649-656.
34. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. JClin Invest 2000, 105:1605-1612.
35. Takagi H., Manabe H., Kawai N., Goto S.N., Umemoto T. Serum high-density and low-density lipoprotein cholesterol is associated with abdominal aortic aneurysm presence: a systematic review and meta-analysis. Int Angiol 2010, 29:371-375.
36. Ghiselli G., Schaefer E.J., Gascon P., Breser H.B. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 1981, 214:1239-1241.
37. Schaefer E.J., Gregg R.E., Ghiselli G., Forte T.M., Ordovas J.M., Zech L.A., et al. Familial apolipoprotein E deficiency. JClin Invest 1986, 78:1206-1219.
38. Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
39. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471.
40. van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005, 437:906-910.
41. Zhang H.L., Wu J., Zhu J. The role of apolipoprotein E in Guillain-Barre syndrome and experimental autoimmune neuritis. JBiomed Biotechnol 2010, 2010:357412.
42. Van Oosten M., Rensen P.C., Van Amersfoort E.S., Van Eck M., Van Dam A.M., Breve J.J., et al. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. JBiol Chem 2001, 276:8820-8824.
43. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003, 163:1117-1125.
44. Tall A.R. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. JIntern Med 2008, 263:256-273.
45. Zhang Y., Zanotti I., Reilly M.P., Glick J.M., Rothblat G.H., Rader D.J. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces invivo. Circulation 2003, 108:661-663.
46. Mackness M.I., Durrington P.N., Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000, 11:383-388.
47. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995, 15:1987-1994.
48. Golledge J., van Bockxmeer F., Jamrozik K., McCann M., Norman P.E. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010, 105:1480-1484.
49. Takagi H., Manabe H., Umemoto T. Ameta-analysis of association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010, 106:753-754.
50. Torsney E., Pirianov G., Charolidi N., Shoreim A., Gaze D., Petrova S., et al. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2012, 32:2678-2686.
51. Jamrozik K., Norman P.E., Spencer C.A., Parsons R.W., Tuohy R., Lawrence-Brown M.M., et al. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med J Aust 2000, 173:345-350.
52. Belin de Chantemele E.J., Vessieres E., Guihot A.L., Toutain B., Loufrani L., Henrion D. Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries. Cardiovasc Res 2010, 86:516-525.